Filing Flows › RenovoRx (RNXT) › Q3 2026
RenovoRx (RNXT) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
RenovoRx (RNXT) reported revenue of $1.1M for the third quarter 2026 (Q3 2026), +301% from a year earlier and +17% from the quarter before. Operating margin was -303.6%, net loss $3.6M (342.1% of revenue).
RenovoRx, Q3 2026: revenue $1.1M (+301% year over year), operating margin -303.6%, net loss $3.6M, operating cash flow −$2.5M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.1M | +17% | +301% |
| Operating profit | −$3.2M | — | — |
| Net earnings | −$3.6M | — | — |
| Operating cash flow | −$2.5M | — | — |
What changed
Revenue was $1.1M in Q3 2026, up 301% year over year and up 17% from the previous quarter.
Gross margin was 82.4%, up 2.3 points from Q3 2025. Operating costs exceeded revenue by $3.2M, an operating margin of -303.6%. Operating expenses grew 21% against revenue growth of 301%. The fastest-growing cost line was SG&A (+66%). The quarter ended with a net loss of $3.6M, wider than the previous quarter's $2.9M loss.
Operating cash flow was −$2.5M. Non-cash charges added back $5K of depreciation and $469K of share-based compensation. Working capital and other items added $634K. Capital expenditures of $19K exceeded it, leaving free cash flow of −$2.6M.
Questions
What was RenovoRx's revenue in the third quarter 2026?
RenovoRx (RNXT) reported revenue of $1.1M for the third quarter 2026 (Q3 2026), +301% from a year earlier and +17% from the quarter before.
Was RenovoRx profitable in the third quarter 2026?
Operating loss was $3.2M (-303.6% of revenue) and net loss $3.6M.
Source: RenovoRx 10-Q on SEC EDGAR.